Plant molecular farming: issues and challenges for Canadian regulators

Author

Marie-France Huot, agr. M.Sc.

Organization

Option consommateurs

Published

2003

Summary

Plant molecular farming (PMF) poses numerous technical and economic challenges for the Canadian regulatory system as well as biotechnology and pharmaceutical companies using this method. This research report deals with the benefits and risks of PMF as regards drug production. In section 1, we review the definition and application of molecular farming, considering the plant species involved and the biopharmaceuticals synthesized. In sections 2 to 4 we discuss the regulatory frameworks for PMF in Canada, the United States and France. In section 5 we consider the technical and economic benefits of PMF. In section 6 we enumerate and explain the risks to human and animal health and the environment potentially engendered by this practice, and also address the methods available to attenuate these risks. Finally, in section 7, this report presents the opinions of farmers and consumers on this new technology.

This document is available in the following language(s):

Third-Party Information Liability Disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

English and French

OCA Funded Research
This research received funding support through the Office of Consumer Affairs' Contributions Program.


Contact information

Address
50 Sainte-Catherine street West, Suite 440
Montreal, Quebec
H2X 3V4
Telephone
(514) 598-7288
Fax
(514) 598-8511

Source: Consumer Policy Research Database

Date Modified: